KALV$13.34
$13.5
Chart
Performance
Key Stats
AI KALV Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralKalVista Pharmaceuticals is a clinical-stage company focusing on hereditary angioedema (HAE). While its primary drug candidate shows promise, the company is pre-revenue and faces significant clinical and regulatory risks. The stock's recent performance has been strong, but its valuation and lack of profitability warrant caution.
Thematic
The company operates in the biotechnology sector, specifically targeting rare diseases. The market for HAE treatments is growing, and KalVista's focus on oral inhibitors addresses an unmet need for convenient treatment options.
Fundamental
As a clinical-stage biopharmaceutical company, KalVista currently has no revenue and is unprofitable, relying on external financing. Its balance sheet shows a significant cash burn and a need for continued capital raises.
Technical
The stock has shown strong recent performance, trading above key moving averages. While some oscillators suggest potential overbought conditions, the overall trend remains positive.
| Factor | Score |
|---|---|
| Rare Disease Focus | 80 |
| Oral Drug Delivery | 75 |
| Clinical Trial Progress | 55 |
| Competitive Landscape | 70 |
| Biotech Funding Environment | 70 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 60 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Focus on Unmet Medical Needs
KalVista Pharmaceuticals is focused on developing drug therapies for diseases with unmet needs, specifically hereditary angioedema (HAE), indicating a strong market positioning for its core product.
Promising Product Pipeline
The company has a lead product candidate, Sebetralstat, a small molecule plasma kallikrein inhibitor for HAE, and is also developing an oral inhibitor for Factor XIIa, also for HAE, indicating a robust development pipeline.
Bearish Points (10)
Negative Earnings Per Share (EPS)
The EPS (TTM) is -3.69, and recent quarterly EPS estimates have also been negative, indicating consistent losses.
Zero Revenue Reported
The company has reported zero revenue for the periods 2022, 2023, 2024, and projected 2025, indicating a lack of commercial sales.
Calendar
November 2016
22
Next Dividend Date
September 2025
4
Next Earnings Date
H: $-0.73
A: $-0.83
L: $-0.95
Profile
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
26.44 USD
The 39 analysts offering 1 year price forecasts for KALV have a max estimate of 39.00 and a min estimate of 18.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Primary direct competitor focusing on sourcing, packing, and distributing avocados globally. Very similar business model to Calavo's core avocado segment.
Weight: 88
Direct competitor in specialty citrus and avocados. Engaged in the agricultural products business, including growing and marketing fresh produce.
Weight: 85
One of the world's largest producers and marketers of fresh fruit and vegetables. A broad competitor in the global fresh produce industry.
Weight: 85
Global producer, marketer, and distributor of fresh fruit and vegetables. A broad competitor in the global fresh produce industry.